TransMedics Group, Inc. (TMDX)
Healthcare · NGM
Price as at 1 Oct 2026, 18:39 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
TransMedics Group, Inc. trades at $78.02, which is 52% above the $37.15 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 81 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 17.4 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
TMDX earnings and analyst estimates
Recommendation mix, 11 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
TMDX passes 4 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$37.12M · 0.0% of book
- Baillie Gifford, BAILLIE GIFFORD & CO$17.80M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$16.49M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$12.79M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$1.86M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in TMDX
Trades in TMDX disclosed by members of Congress and executive-branch officials, latest first:
- Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 15 May 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 29 Jul 2024 · disclosed 22 Sept 2026
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 8 Jul 2024 · disclosed 22 Sept 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
TMDX peers
The largest companies in the same industry (Medical Devices), then in the same sector.
- PHG Koninklijke Philips N.V.
- PEN Penumbra, Inc.
- GMED Globus Medical, Inc.
- BIO Bio-Rad Laboratories, Inc.
- LIVN LivaNova PLC
- IRTC iRhythm Holdings, Inc.
- NEOG Neogen Corporation
- AXGN Axogen, Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is TransMedics Group, Inc. (TMDX) undervalued?
Against our fair value estimate of $37.15, TMDX at $78.02 is 52% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own TMDX?
6 of the institutions we track reported a position in TMDX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is TMDX's P/E ratio?
TMDX trades at 17.4 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its TMDX data?
Fundamentals for TMDX come from company filings and exchange data, as listed on NGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 18:39 UTC and is delayed. Our data quality score for this company is 96/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for TMDX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.